SCHEMBL1779428

SCHEMBL1779428

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)c2cc(C)[nH]n2)c2cc(C(=O)NC(C)(C)c3ccccc3)sc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.40
BCR P11274 2/20 0.40
AURKA O14965 1/20 0.37
RXFP1 Q9HBX9 2/20 0.36
MAPT P10636 7/20 0.35
KDM4E B2RXH2 3/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RNASEL Q05823 1/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
TP53 P04637 3/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
RET P07949 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1780035 0.91 KMT2A (0.38) RXFP1MAPTKDM4EKMT2ALMNA
SCHEMBL1779165 0.89 KDM4E (0.38) ABL1RXFP1MAPTKDM4EKMT2A
SCHEMBL1778917 0.88 AURKA (0.48) ABL1BCRAURKA
SCHEMBL1781046 0.88 ALDH1A1 (0.38) RXFP1MAPTKDM4EKMT2ALMNA
SCHEMBL1778679 0.86 MAPT (0.37) ABL1BCRAURKARXFP1MAPT
SCHEMBL1779652 0.85 RXFP1 (0.36) ABL1BCRAURKARXFP1MAPT
SCHEMBL1433343 0.85 ABL1 (0.39) ABL1BCRAURKARXFP1MAPT
SCHEMBL1778509 0.85 RXFP1 (0.41) RXFP1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL1781304 0.85 KDR (0.37) ABL1BCRAURKARXFP1MAPT
SCHEMBL1433182 0.84 RXFP1 (0.38) ABL1BCRAURKARXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 ABL1 397/4885BCR 1047/4885AURKA 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.